Milestone Pharmaceuticals Inc.
MIST
Rank in Stocks
#20050
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in... Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
Share Price
$0.738
Last synced: 2026-11-09
Market Cap
$91.88M
Change (1 day)
-3.25%
Change (1 year)
-61.36%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Milestone Pharmaceuticals Inc. (MIST)
Category
Healthcare
EPS for Milestone Pharmaceuticals Inc. (MIST)
EPS as of June 2026 TTM: $-0.69
According to Milestone Pharmaceuticals Inc.'s latest financial reports, its current EPS (TTM) is $-0.69. At the end of 2025 the company had an EPS of $-0.75, a decrease compared to its 2024 EPS of $-0.67.
EPS history for Milestone Pharmaceuticals Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.69 | -8.00% |
| 2025 | $-0.75 | 11.94% |
| 2024 | $-0.67 | -51.80% |
| 2023 | $-1.39 | 2.96% |
| 2022 | $-1.35 | 32.35% |
| 2021 | $-1.02 | -40.00% |
| 2020 | $-1.70 | -51.43% |
| 2019 | $-3.50 | 257.14% |
| 2018 | $-0.98 | 188.24% |
| 2017 | $-0.34 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,369.57% |
US
|
|
| $-7.07 | 924.64% |
US
|
|
| $-5.29 | 666.67% |
AU
|
|
| $12.88 | -1,966.68% |
BE
|
|
| $21.56 | -3,224.64% |
NL
|
Questions about Milestone Pharmaceuticals Inc.'s earnings per share (EPS)
What is Milestone Pharmaceuticals Inc.'s earnings per share (EPS)?
Milestone Pharmaceuticals Inc.'s earnings per share (EPS) over the last twelve months is $-0.69, as of Jun 2026.
What was Milestone Pharmaceuticals Inc.'s earnings per share (EPS) in 2025?
In 2025, Milestone Pharmaceuticals Inc.'s earnings per share (EPS) was $-0.75, compared with $-0.67 in 2024.
How has Milestone Pharmaceuticals Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Milestone Pharmaceuticals Inc.'s earnings per share (EPS) was highest in 2024 ($-0.67) and lowest in 2020 ($-1.70).
How does Milestone Pharmaceuticals Inc.'s earnings per share (EPS) compare with similar companies?
Milestone Pharmaceuticals Inc.'s earnings per share (EPS) ($-0.69) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.